Skip to content
Peregrine
  • Home
  • About Us
    • Company Overview
    • Our Mission
  • Our Funds
  • Portfolio
  • Team
  • ESG & Impact
  • News
  • Contact
  • Home
  • About Us
    • Company Overview
    • Our Mission
  • Our Funds
  • Portfolio
  • Team
  • ESG & Impact
  • News
  • Contact

News

Nir Altschuler, CEO of CartiHeal, following the company’s acquisition by Bioventus

CartiHeal, makes biggest Israeli biomed exit of 2023

Read More

BioProtect Balloon ImplantTM System has been cleared by the FDA

Read More
Cordio Medical

AstraZeneca and Bellvitge University Hospital launch pilot of Cordio Medical’s HearO heart failure monitoring platform

Read More

KAHR Medical’s DSP107 demonstrates deep and durable responses in Phase I trial of advanced solid tumors

Read More
Forbes logo, coverage of Cordio Medical and its heart failure monitoring technology

Forbes features Cordio Medical’s AI-powered HearO platform for heart failure monitoring

Read More
Ribon Therapeutics lab coats with company logo, first patient dosed in clinical trial

Ribon Therapeutics doses first patient in Phase 1 study of first-in-class PARP14 inhibitor RBN-3143

Read More

Restore Medical reports successful preliminary results from ContraBand™ First-in-Human study

Read More

BioProtect presented successful outcomes from its phase I/II study

Read More
Levation Pharma Logo

Levation Pharma, Ltd. received an FDA clearance to initiate Phase I/II of LEV102

Read More
EndoStream Medical device illustration, first US clinical trial case

EndoStream Medical announced they are conducting their first case in the US as part of the company’s Clinical Trial

Read More
Page1 Page2 Page3 Page4 Page5
  • Homepage
  • About Us
  • Our Funds
  • Portfolio
  • Team
  • ESG AND IMPACT
  • News
  • Contact
  • Homepage
  • About Us
  • Our Funds
  • Portfolio
  • Team
  • ESG AND IMPACT
  • News
  • Contact
Linkedin-in
  • Terms of Use
  • Privacy Policy
  • Accessibility Statment
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Accessibility Statment
  • Cookie Policy
©All rights reserved to Peregrine 2026

site by: 

razgroup-logo
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}